Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Chronic use can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence. Compulsive redosing and cravings may occur, though its less stimulating profile compared to MDMA appears to be associated with somewhat less compulsive redosing behavior than related drugs.
Withdrawal effects may occur if a person suddenly stops usage after addiction has developed, though specific physical dependence symptoms are not well characterized due to limited research history.
The exact toxic dosage is unknown due to very limited history of human usage and lack of scientific study.
Long-term use may be cardiotoxic due to 5-HT2B receptor agonism, which has been associated with valvular heart disease; this risk is theoretical based on the mechanism shared with other 5-HT2B agonists rather than documented cases specific to 5-MAPB.
Rodent studies indicate dose-dependent serotonergic neurotoxicity similar to MDMA, and the compound may also be a dopaminergic neurotoxin; relevance to occasional human use at typical doses remains unclear.
As with other amphetamine-class compounds, abuse at high dosages for prolonged periods can potentially result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Approximately 5-15% of those experiencing amphetamine-induced psychosis may not fully recover, though psychosis very rarely arises from typical use patterns.
5-MAPB emerged on the designer drug market around 2010 as part of the wave of novel benzofuran entactogens developed as alternatives to controlled substances like MDMA. The compound was first formally identified and documented by researchers in 2013, with the initial scientific literature…
Not specifically listed in the Controlled Drugs and Substances Act. May be considered an analogue of Schedule I amphetamines due to structural relation to MDMA. This legal interpretation has not been tested in court.
Scheduled under the government decree on psychoactive substances banned from the consumer market.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production, import for market distribution, administration to others, and trading are criminally punishable. Possession is prohibited but not subject to criminal penalty.
As of July 2021, not listed among prohibited substances and remains legal for possession and personal use.
Initially placed under a Temporary Class Drug order in June 2013 following ACMD recommendation. Permanently classified as a Class B, Schedule 1 substance on June 10, 2014, alongside all other benzofuran entactogens and structurally related compounds.
Classified as a controlled substance since October 2015.
Classified as a narcotic substance since May 9, 2018, alongside other benzofuran-derived compounds.
Designated as a controlled substance effective August 15, 2015.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Not specifically scheduled under federal law. However, due to structural similarity to MDA and MDMA, sales for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act, though no such cases are known.
12 sources cited